The McMinn Centre, 25 Highfield Road, Edgbaston, Birmingham B15 3DP, UK.
Int Orthop. 2011 Feb;35(2):231-7. doi: 10.1007/s00264-010-1148-8. Epub 2010 Nov 16.
The best indication for hip resurfacing is a young active patient with severe hip arthritis, good hip morphology and reasonable bone quality. With revision of either component for any reason as the endpoint, there were 68 revisions in our series of 3,095 consecutive Birmingham Hip Resurfacings (BHR) (1997-2009), including all diagnoses in all ages. This equates to a revision rate of 2.2% and survivorships of 99, 97 and 96% at five, ten and 13 years, respectively. In patients under 55 years with osteoarthritis, the survivorship is 99 and 98% at ten and 13 years. These results provide medium-term evidence that BHR when performed well in properly selected patients offers excellent outcomes and implant survivorship. Small changes to implant materials and design can affect joint function and survivorship significantly as seen from the withdrawal of certain resurfacing devices recently from clinical use. The clinical history of one device cannot be extrapolated to other devices.
髋关节表面置换术的最佳适应证是年轻、活跃、患有严重髋关节关节炎、髋关节形态良好且骨质质量合理的患者。以任何原因翻修为终点,在我们的 3095 例连续 Birmingham Hip Resurfacings(BHR)(1997-2009 年)系列中,有 68 例翻修,包括所有年龄段的所有诊断。这相当于翻修率为 2.2%,5 年、10 年和 13 年的生存率分别为 99%、97%和 96%。在 55 岁以下的骨关节炎患者中,10 年和 13 年的生存率分别为 99%和 98%。这些结果提供了中期证据,表明 BHR 在适当选择的患者中进行时,可提供出色的结果和植入物生存率。植入物材料和设计的微小变化可显著影响关节功能和生存率,最近某些髋关节表面置换装置已从临床应用中撤出。一种装置的临床历史不能推断到其他装置。